Elizabeth M. Gore, MD, FACR

Publications

• Erratum to: Spratt DE, Liu VYT, Michalski J, Davicioni E, Berlin A, Simko JP, Efstathiou JA, Tran PT, Sandler HM, Hall WA, Thompson DJS, Parliament MB, Dayes IS, Correa RJM, Robertson JM, Gore EM, Doncals DE, Vigneault E, Souhami L, Karrison TG, Feng FY. Genomic classifier performance in intermediate-risk prostate cancer: results from NRG Oncology/RTOG 0126 randomized phase 3 trial. Int J Radiat Oncol Biol Phys 2023;117:370-377.

  (Spratt DE, Liu VYT, Michalski J, Davicioni E, Berlin A, Simko JP, Efstathiou JA, Tran PT, Sandler HM, Hall WA, Thompson DJS, Parliament MB, Dayes IS, Correa RJM, Robertson JM, Gore EM, Doncals DE, Vigneault E, Souhami L, Karrison TG, Feng FY.) Int J Radiat Oncol Biol Phys. 2024 Dec 01;120(5):1461 PMID: 39320298 SCOPUS ID: 2-s2.0-85204708740 09/25/2024

• 5-hydroxymethylcytosine sequencing in plasma cell-free DNA identifies unique epigenomic features in prostate cancer patients resistant to androgen deprivation therapies.

  (Li Q, Huang CC, Huang S, Tian Y, Huang J, Bitaraf A, Dong X, Nevalanen MT, Patel M, Wong J, Zhang J, Manley BJ, Park JY, Kohli M, Gore EM, Kilari D, Wang L.) medRxiv. 2024 Oct 17 PMID: 37904926 PMCID: PMC10615016 10/31/2023

• Patient-reported outcomes (PROs) in NRG Oncology RTOG 0436: a phase III trial evaluating the addition of cetuximab to paclitaxel, cisplatin, and radiation for esophageal cancer treated without surgery.

  (Kachnic LA, Winter K, Suntharalingam M, Ilson D, Konski A, Lloyd S, McAvoy SA, Lad T, Olowokure OG, Samson P, Gore EM, Meyer JE, Videtic GMM, Clump DA, Raben A, Kayaleh O, Barker J Jr, Haddock MG, Hopkins JO, Bruner DW.) Qual Life Res. 2024 Oct;33(10):2833-2844 PMID: 39066879 SCOPUS ID: 2-s2.0-85200043165 07/28/2024

• Cardiovascular Mortality and Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-term Update of NRG/RTOG 9202.

  (Mak KS, Scannell Bryan M, Dignam JJ, Shipley WU, Lin Y, Peters CA, Gore EM, Rosenthal SA, Zeitzer KL, D'Souza DP, Horwitz EM, Pisansky TM, Maier JM, Chafe SM, Robin TP, Roach M 3rd, Tran PT, Souhami L, Michalski JM, Hartford AC, Feng FY, Sandler HM, Efstathiou JA.) Eur Urol Focus. 2024 Mar;10(2):271-278 PMID: 38307806 PMCID: PMC11257781 SCOPUS ID: 2-s2.0-85184044805 02/03/2024

• Multicenter Phase 1b/2a Clinical Trial of Radioprotectant BIO 300 Oral Suspension for Patients With Non-Small Cell Lung Cancer Receiving Concurrent Chemoradiotherapy.

  (Simone CB 2nd, Serebrenik AA, Gore EM, Mohindra P, Brown SL, Wang D, Chetty IJ, Vujaskovic Z, Menon S, Thompson J, Fine G, Kaytor MD, Movsas B.) Int J Radiat Oncol Biol Phys. 2024 Feb 01;118(2):404-414 PMID: 37652301 SCOPUS ID: 2-s2.0-85172016695 09/01/2023

• The Inherited KRAS-variant as a Biomarker of Cetuximab Response in NSCLC.

  (Weidhaas JB, Hu C, Komaki R, Masters GA, Blumenschein GR, Chang JY, Lu B, Dicker AP, Bogart JA, Garces YI, Narayan S, Robinson CG, Kavadi VS, Greenberger JS, Koprowski CD, Welsh J, Gore EM, MacRae RM, Paulus R, Bradley JD.) Cancer Res Commun. 2023 Oct 11;3(10):2074-2081 PMID: 37728512 PMCID: PMC10566451 09/20/2023

• Development of a comprehensive cardiac atlas on a 1.5 Tesla Magnetic Resonance Linear Accelerator.

  (Schottstaedt AM, Paulson ES, Rubenstein JC, Chen X, Omari EA, Li XA, Schultz CJ, Puckett LL, Robinson CG, Alongi F, Gore EM, Hall WA.) Phys Imaging Radiat Oncol. 2023 Oct;28:100504 PMID: 38035207 PMCID: PMC10682663 11/30/2023

• Genomic Classifier Performance in Intermediate-Risk Prostate Cancer: Results From NRG Oncology/RTOG 0126 Randomized Phase 3 Trial.

  (Spratt DE, Liu VYT, Michalski J, Davicioni E, Berlin A, Simko JP, Efstathiou JA, Tran PT, Sandler HM, Hall WA, Thompson DJS, Parliament MB, Dayes IS, Correa RJM, Robertson JM, Gore EM, Doncals DE, Vigneault E, Souhami L, Karrison TG, Feng FY.) Int J Radiat Oncol Biol Phys. 2023 Oct 01;117(2):370-377 PMID: 37137444 PMCID: PMC10949135 SCOPUS ID: 2-s2.0-85163341124 05/04/2023

• Dose-Escalated Radiation Alone or in Combination With Short-Term Total Androgen Suppression for Intermediate-Risk Prostate Cancer: Patient-Reported Outcomes From NRG/Radiation Therapy Oncology Group 0815 Randomized Trial.

  (Movsas B, Rodgers JP, Elshaikh MA, Martinez AA, Morton GC, Krauss DJ, Yan D, Citrin DE, Hershatter BW, Michalski JM, Ellis RJ, Kavadi VS, Gore EM, Gustafson GS, Schulz CA, Velker VM, Olson AC, Cury FL, Papagikos MA, Karrison TG, Sandler HM, Bruner DW.) J Clin Oncol. 2023 Jun 10;41(17):3217-3224 PMID: 37104723 PMCID: PMC10256387 SCOPUS ID: 2-s2.0-85163236689 04/27/2023

• Definitive Chemoradiation Associated with Improved Survival Outcomes in Patients with Synchronous Oligometastatic Esophageal Cancer.

  (Matoska T, Banerjee A, Shreenivas A, Jurkowski L, Shukla ME, Gore EM, Linsky P, Gasparri M, George B, Johnstone C, Johnstone D, Puckett LL.) Cancers (Basel). 2023 Apr 28;15(9) PMID: 37173988 PMCID: PMC10177457 SCOPUS ID: 2-s2.0-85159164697 05/13/2023

• Development of a comprehensive cardiac atlas on a 1.5 Tesla Magnetic Resonance Linear Accelerator

  (Schottstaedt AM, Paulson ES, Rubenstein JC, Chen X, Omari EA, Li XA, Schultz CJ, Puckett LL, Robinson CG, Alongi F, Gore EM, Hall WA.) Physics and Imaging in Radiation Oncology. October 2023;28 SCOPUS ID: 2-s2.0-85176356378 10/01/2023

• Consensus Quality Measures and Dose Constraints for Lung Cancer From the Veterans Affairs Radiation Oncology Quality Surveillance Program and ASTRO Expert Panel.

  (Puckett LL, Titi M, Kujundzic K, Dawes SL, Gore EM, Katsoulakis E, Park JH, Solanki AA, Kapoor R, Kelly M, Palta J, Chetty IJ, Jabbour SK, Liao Z, Movsas B, Thomas CR Jr, Timmerman RD, Werner-Wasik M, Kudner R, Wilson E, Simone CB 2nd.) Pract Radiat Oncol. 2023;13(5):413-428 PMID: 37075838 SCOPUS ID: 2-s2.0-85163287912 04/20/2023